Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement-Reference-Cited by-同舟云学术

Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement

Published:2017-04-24 Issue:6 Volume:13 Page:597-604
ISSN:1742-5255
Container-title:Expert Opinion on Drug Metabolism & Toxicology
language:en
Short-container-title:Expert Opinion on Drug Metabolism & Toxicology

Author:

Bouman CAM¹,van Herwaarden N¹,van den Hoogen FHJ¹²,van der Maas A¹,van den Bemt BJF³⁴,den Broeder AA¹²

Affiliation:

1. Department of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands

2. Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands

3. Department of Pharmacy, Sint Maartenskliniek, Nijmegen, The Netherlands

4. Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands

Funder

Sint Maartenskliniek

Publisher

Informa UK Limited

Subject

Pharmacology,Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425255.2017.1320390

Reference35 articles.

1. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis

2. Dutch medication tarifs. Medicijnkosten. Available from: www.medicijnkosten.nl

3. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis

4. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial;Rheumatology International;2024-07-24

2. Development and validation of a novel therapeutic drug monitoring-based nomogram for prediction of primary endoscopic response to anti-TNF therapy in active Crohn’s disease;Therapeutic Advances in Gastroenterology;2024-01

3. Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine;BioDrugs;2022-10-31

4. Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider;RMD Open;2022-06

5. EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases;Annals of the Rheumatic Diseases;2022-05-12